Kay on Rheumatology

 
 
  • Could This Rash Mean Malignancy?   Jonathan Kay describes a patient with an extensive rash that initially suggested dermatomyositis but turned out to auger something more serious.
  • Biologics or Not in RA? This Test Could Help Decide   The MBDA score may be able to distinguish between patients who need biologic therapy and those who will do fine on nonbiologic therapy.
  • Drugs for the Rarest Rheumatic Diseases   An orphan drug is not a drug that has lost its parent compounds.
  • Biosimilars: As Good as the Originals?   Dr. Jonathan Kay reviews biosimilar studies presented at EULAR 2014.
  • Using the Latest Psoriatic Arthritis Therapy   Dr. Jonathan Kay discusses the recent approval of apremilast for psoriatic arthritis. What will its therapeutic role be?
  • Is This Patient's Cryoglobulin Hiding Something?   Negative HCV RNA in a man with mixed cryoglobulinemia -- crack the case.
  • Vasculopathy: A Treatment on the Horizon?   The identification of the loss-of-function mutation that results in ADA2 deficiency and the phenotype of polyarteritis nodosa could lead to effective treatments for this vasculopathy.
  • Two Tests Not to Delay in RA   Dr. Jonathan Kay discusses a new study asking whether acute-phase reactant profiles correlate with clinical disease activity in patients with rheumatoid arthritis.
  • Biosimilars: Is It Safe to Switch?   Dr. Jonathan Kay discusses the big questions surrounding biosimilar medications in rheumatology: Are they safe and effective, and can they be interchanged with the reference compound?
  • Something's Fishy in Rheumatoid Arthritis   Does adding fish oil to DMARD therapy provide benefit in patients with rheumatoid arthritis?
  • Triple Therapy in RA: The Debate Continues Touching on data presented at the American College of Rheumatology 2013 Annual Meeting, Dr. Jonathan Kay discusses the benefits and drawbacks of triple therapy in rheumatoid arthritis.
  • How Gout Changed History   Dr. Jon Kay visits Madrid’s Prado Museum for a look at how the 'disease of kings' altered the course of European history.
  • Did RA Therapy Just Get Cheaper?   Dr. Jonathan Kay discusses a recent study that could potentially change the way rheumatoid arthritis is managed.
  • Four Important Arthritis Studies   Dr. Jonathan Kay reviews new data on the efficacy and safety of biosimilar medications in rheumatologic conditions.
  • Choosing a Biologic in Rheumatoid Arthritis   Dr. Kay summarizes recent comparative effectiveness trials of biologic therapy for RA.
  • Running Out of Lupus Drug Options: A Case   Jonathan Kay reports the case of a woman who is proving to be intolerant of lupus treatments.
  • Do Cherries Really Work in Gout?   Patients suffering from gout often eat cherries to prevent gout attacks. Is there any scientific basis for this?
  • Defining Erosive Disease in Rheumatoid Arthritis   A specific definition brings erosions back as a criterion in the definition of rheumatoid arthritis
  • Lupus Plus Cranial Neuropathy: A Treatment to Try   Dr. Jon Kay discusses the challenging case of a patient with systemic lupus erythematosus now presenting with cranial nerve dysfunction.
  • Prophylaxis, Treatment, and Foods to Avoid in Gout   Dr. Jonathon Kay on the American College of Rheumatology’s new gout management guidelines.